Treatment of parkinsonism with L-threo-3,4-dihydroxyphenylserine: a pharmacokinetic study.

Abstract

We have examined the kinetics of oral L-threo-3,4-dihydroxyphenylserine (DOPS) alone and combined with peripheral decarboxylase inhibitors in patients with Parkinson's disease and other degenerative diseases of the brain. Combined administration of L-threo-DOPS and carbidopa or benserazide produced higher plasma concentrations of L-threo-DOPS and suppressed the increase in plasma norepinephrine. This finding indicates some advantages of combined therapy with L-threo-DOPS and decarboxylase inhibitors. Measurable quantities of DL-threo-DOPS were found in the CSF during repeated administration, but there was no consistent change in norepinephrine concentration.

• Authors: T Suzuki, S Sakoda, M Ueji, S Kishimoto, A Hayashi, T Kondo, H Narabayashi
• Journal: Neurology (Neurology) Vol. 34 Issue 11 Pg. 1446-50 (Nov 1984) ISSN: 0028-3878 [Print] United States
• PMID: 6436731 (Publication Type: Journal Article)

Chemical References

• Serine
• Droxidopa
• Carbidopa

Topics

• Adult
• Aged
• Carbidopa (metabolism, therapeutic use)
• Cerebellar Diseases (drug therapy)
• Droxidopa (metabolism, therapeutic use)
• Female
• Humans
• Kinetics
• Male
• Middle Aged
• Olivary Nucleus
• Parkinson Disease (drug therapy)
• Pons
• Serine (analogs & derivatives)